This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jørgensen, J. O. L. Articles by Ørskov, H. Search for Related Content PubMed PubMed Citation Articles by Jørgensen, J. O. L. Articles by Ørskov, H. Related Collections Neuroendocrinology and Pituitary

Cotreatment of Acromegaly with a Somatostatin Analog and a Growth Hormone Receptor Antagonist

Medical Department M (Endocrinology and Diabetes) (J.O.L.J., J.F., J.-W.C., H.Ø.), Aarhus University Hospital, DK-8000 C Aarhus, Denmark; Department of Endocrinology, Rigshospitalet (U.F.-R.), DK-2200 Copenhagen, Denmark; Department of Medicine and Endocrinology, Herlev Sygehus (L.Ø.K.), DK-2730 Copenhagen, Denmark; and Department of Endocrinology (C.H.), Odense University Hospital, DK-5000 Odense, Denmark

Address all correspondence and requests for reprints to: J. O. L. Jørgensen, Medical Department M, Aarhus University Hospital, Norrebrogade 44, DK-8000 C Aarhus, Denmark. E-mail: jolj{at}dadlnet.dk.

Context: Pegvisomant is a GH receptor antagonist that blocks the peripheral actions of GH in acromegaly. Pegvisomant, in contrast to somatostatin (SMS) analogs, does not suppress the activity of the GH-producing adenoma.

Objective: We assessed the effects of cotreatment with pegvisomant and SMS in acromegaly on GH secretion, IGF-I levels, and glucose tolerance.

Design, Patients, and Interventions: Eleven patients with persistent disease despite previous therapy underwent the following fixed treatment algorithm: 1) on SMS therapy, 2) off therapy for 2 months, 3) 6-wk treatment with 10 mg/d pegvisomant, 4) 6-wk treatment with 15 mg/d pegvisomant, and 5) 3-month treatment with 15 mg pegvisomant plus SMS. Blood was sampled in the fasting state and during an oral glucose tolerance test.

Results: Total serum IGF-I levels (micrograms per liter) decreased after pegvisomant, but the lowest levels were obtained with cotreatment [458 ± 67 (SMS), 562 ± 78 (active), 376 ± 51 (10 mg), 269 (15 mg), 195 ± 24 (combined) (P < 0.0001)]. Free and bioactive IGF-I changed in a similar pattern. Steady-state pegvisomant levels (micrograms per liter) were obtained, but SMS cotreatment increased pegvisomant levels by 20% (P = 0.02) [2631 ± 616 (10 mg), 6536 ± 1413 (15 mg), 8030 ± 1914 (combined)]. Pegvisomant increased endogenous GH levels (micrograms per liter), which was countered by SMS cotreatment [5.1 ± 1.3 (SMS), 8.9 ± 2.9 (active), 14.6 ± 4.9 (10 mg), 19.7 ± 6.5 (15 mg), 11.8 ± 2.8 (combined) (P < 0.01)]. Plasma glucose levels (millimoles per liter) were highest during SMS and lowest during pegvisomant 15 mg [2-h oral glucose tolerance test: 10.3 ± 0.7 (SMS), 8.9 ± 0.7 (active), 7.2 ± 0.7 (10 mg), 6.5 ± 0.5 (15 mg), 8.0 ± 0.8 (combined) (P = 0.02)].

Conclusions: Dual blockade of the GH axis with pegvisomant and a SMS analog is feasible in acromegaly.

This article has been cited by other articles:

				C. E. Higham and P. J. Trainer Growth hormone excess and the development of growth hormone receptor antagonists Exp Physiol, November 1, 2008; 93(11): 1157 - 1169. [Abstract] [Full Text] [PDF]

				S. J. C. M. M. Neggers, M. O. van Aken, W. W. de Herder, R. A. Feelders, J. A. M. J. L. Janssen, X. Badia, S. M. Webb, and A. J. van der Lely Quality of Life in Acromegalic Patients during Long-Term Somatostatin Analog Treatment with and without Pegvisomant J. Clin. Endocrinol. Metab., October 1, 2008; 93(10): 3853 - 3859. [Abstract] [Full Text] [PDF]

				C. Nielsen, L. C. Gormsen, N. Jessen, S. B. Pedersen, N. Moller, S. Lund, and J. O. L. Jorgensen Growth Hormone Signaling in Vivo in Human Muscle and Adipose Tissue: Impact of Insulin, Substrate Background, and Growth Hormone Receptor Blockade J. Clin. Endocrinol. Metab., July 1, 2008; 93(7): 2842 - 2850. [Abstract] [Full Text] [PDF]

				M. P Matta, E. Couture, L. Cazals, D. Vezzosi, A. Bennet, and P. Caron Impaired quality of life of patients with acromegaly: control of GH/IGF-I excess improves psychological subscale appearance Eur. J. Endocrinol., March 1, 2008; 158(3): 305 - 310. [Abstract] [Full Text] [PDF]

				R. Lindberg-Larsen, N. Moller, O. Schmitz, S. Nielsen, M. Andersen, H. Orskov, and J. O. L. Jorgensen The Impact of Pegvisomant Treatment on Substrate Metabolism and Insulin Sensitivity in Patients with Acromegaly J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1724 - 1728. [Abstract] [Full Text] [PDF]

				S. Melmed Acromegaly N. Engl. J. Med., December 14, 2006; 355(24): 2558 - 2573. [Full Text] [PDF]

				S. O. Akintoye, M. H. Kelly, B. Brillante, N. Cherman, S. Turner, J. A. Butman, P. G. Robey, and M. T. Collins Pegvisomant for the Treatment of gsp-Mediated Growth Hormone Excess in Patients with McCune-Albright Syndrome J. Clin. Endocrinol. Metab., August 1, 2006; 91(8): 2960 - 2966. [Abstract] [Full Text] [PDF]

				A. Colao, R. Pivonello, R. S Auriemma, M. C. De Martino, M. Bidlingmaier, F. Briganti, F. Tortora, P. Burman, I. A Kourides, C. J Strasburger, et al. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. Eur. J. Endocrinol., March 1, 2006; 154(3): 467 - 477. [Abstract] [Full Text] [PDF]